Abstract:Objective To verify the efficacy and safety of intravesical instillation of Cystistat in reducing complications caused by intravesical chemotherapy after TUR-BT in non-muscle invasive bladder cancer patients. Methods One hundred and twenty patients who met the inclusion/exclusion criteria were enrolled into this multi-centered, randomized and blank controlled clinical study. Selected patients were randomized into the observation group and control group. TUR-BT was carried out in both groups followed by pirarubicin (THP) and Cystistat intravesical instillation in the observation group, and THP intravesical instillation alone in control group. Visual analog scale (VAS) was used as the primary efficacy variable. The secondary efficacy variables were assessments of hematuria and bladder irritation symptoms. Adverse events, laboratory tests and changes of vital signs before and after treatment were strictly observed during observation to evaluate the efficacy and safety of Cystistat.Results Demographics and baseline characteristics were comparable in both groups. The differences and the improvement rate of VAS score in the 2 groups were significant, both P＜0.01. The changes of VAS score and the improvement rate before and after treatment were (2. 24±1.70) and (92. 92±14.76) % in observation group and (0. 70±1.82) and (20. 59±87.34)% in control group respectively. According to the covariance analysis, there were significant differences in changes of VAS score between the observation group and the control group. Also, the improvement rate of VAS score was significant from visit 2. The urine frequency decreased from 9.06±4.09 to 6. 69±2.89 in observation group and increased from 8. 85±3. 32 to 10. 15±4.40 in control group, P＜0.01. There were also significant differences in changes of nocturia before and after treatment between these two groups (P＜0.01), the nocturia decreased from 2. 88±1.74 to 1. 47±1.62 in observation group and 3. 22±2.30 to 2.91±1.73 in control group, respectively. The changes of WHO assessment for hematuria,urgency and dysuria were not significantly different between the 2 groups. No Cystistat related adverse event was observed. Conclusions Cystistat combined instillation can significantly improve the VAS score of patients with chemotherapeutic agent instillation. Relief of bladder pain, frequency and nocturia are more rapidly and more durable in Cystistat combined instillation group. The improvement is more effective in patients with a high VAS score. Cystistat instillation with chemotherapeutics agents is both well tolerated and safe.

Homologous Targeting and Adhesion Abilities of Cellular Microvesicles for Enhanced Intravesical Therapy of Bladder Cancer

R11 modified tumor cell membrane nanovesicle-camouflaged nanoparticles with enhanced targeting and mucus-penetrating efficiency for intravesical chemotherapy for bladder cancer

Pre-instillation of Tumor Microparticles Enhances Intravesical Chemotherapy of Nonmuscle-Invasive Bladder Cancer Through a Lysosomal Pathway.

[Mechanism of Intravesical Instillation of Pirarubicin for Preventing Recurrence of Non-Muscle Invasive Bladder Cancer].

A Selective-Tumor-Penetrating Strategy Via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer

Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer

Mucoadhesive Cationic Polypeptide Nanogel with Enhanced Penetration for Efficient Intravesical Chemotherapy of Bladder Cancer

Bioengineered bacterial outer membrane vesicles encapsulated Polybia–mastoparan I fusion peptide as a promising nanoplatform for bladder cancer immune-modulatory chemotherapy

Combination of Cystistat and Pirarubicin Intravesical Instillation in Reducing Intravesical Chemotherapy Complications: a Multi-Center Clinical Study

A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer

NIR Molecule Induced Self-Assembled Nanoparticles for Synergistic in Vivo Chemo-Photothermal Therapy of Bladder Cancer

An Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived&nbsp;Mimetic Nanovesicles to Treat Bladder Cancer

Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers

Mild magnetic hyperthermia-activated immuno-responses for primary bladder cancer therapy

Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer

AN INTERNAL CROSS-LINKED POLYMERIC NANOPARTICLE WITH DUAL SENSITIVITY FOR COMBINATION THERAPY OF MUSCLE-INVASIVE BLADDER CANCER

A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer

Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer

Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation.

Data from Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer

Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer